We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App




Dynamic Trends Seen in Clinical Laboratory Services

By LabMedica International staff writers
Posted on 20 Jan 2014
Print article
The constant pressure to reduce healthcare spending is shifting healthcare utilization in favor of the laboratory. Approximately 80% of physicians' diagnoses are a result of laboratory tests, and a number of these tests are sent to clinical lab service providers. Kalorama Information (New York, NY, USA) has published a new report based on a research study of the market for clinical lab services.

A trend towards preventive and risk factor testing is noted in several disciplines, particularly in the areas of oncology, endocrinology, and gynecology. Physicians in these areas are taking advantage of testing for early detection and disease prevention. Key market data provided includes hospital, physician, and independent lab statistics, major tests performed by clinical lab companies, disease incidence, trends driving lab business, and a market forecast to 2018. The geographic breakout of the clinical lab services market includes the US, Europe and Asia, and specific breakouts for Germany, Japan, China, India, and Brazil.

Some of the other issues and trends explored in the report include US demographics, types of specialty tests, growing competition, increasing life expectancy, the growing incidence of disease, and developments in personalized medicine.

A competitive analysis of leading clinical laboratory providers includes Quest Diagnostics, Inc., Laboratory Corporation of America, Genomic Health, Genoptix, Genzyme Corporation, DaVita, Clarient, Spectra Labs, and Bio-Reference Labs.

The most important part of Kalorama's efforts is its analysis of company activities and their significance in the marketplace. Historical data is provided for the years 2008–2012, with forecast data provided for 2013 through 2017. A competitive analysis is provided for the year 2013. The predicted market analysis for 2013–2017 was largely based on demographic trends, new developments, company performance trends, mergers and acquisitions, and national expansion.

Related Links:

Kalorama Information



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The revolutionary autonomous blood draw technology is witnessing growing demands (Photo courtesy of Vitestro)

Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing

Blood drawing is performed billions of times each year worldwide, playing a critical role in diagnostic procedures. Despite its importance, clinical laboratories are dealing with significant staff shortages,... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.